Current analytical chemistry vol:1 issue:2 pages:121-127
During long-term treatment with STI-571 (Gleevec(R), Glivec(R), Imatinib), it is possible that tumor cells change their expression of proteins in order La. to reduce their exposure to STI-571. This would eventually result in reduced activity. In order to evaluate this possibility, we have developed an analytical technique to determine intrinsic cellular concentrations of STI-571 in tumor cells which have been manipulated to generate lines with differential expression of the multi drug resistance protein Pgp-170. A high-speed isocratic high-performance liquid chromatographic method coupled to tandem mass spectrometry for the quantification of the new anticancer agent STI-571 in cultured tumor cells is described.